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Background: Modeling of deep brain stimulation electric fields and anatomy-based
software might improve post-operative management of patients with Parkinson’s disease
(PD) who have benefitted from subthalamic nucleus deep brain stimulation (STN-DBS).
Objective: We compared clinical and software-guided determination of the thresholds
for current diffusion to the pyramidal tract, the most frequent limiting side effect in
post-operative management of STN-DBS PD patients.
Methods: We assessed monopolar reviews in 16 consecutive STN-DBS PD patients
and retrospectively compared clinical capsular thresholds, which had been assessed
according to standard clinical practice, to those predicted by volume of tissue activated
(VTA) model software. All the modeling steps were performed blinded from patients’
clinical evaluations.
Results: At the group level, we found a significant correlation (p = 0.0001) when
performing statistical analysis on the z-scored capsular thresholds, but with a low
regression coefficient (r = 0.2445). When considering intra-patient analysis, we found
significant correlations (p < 0.05) between capsular threshold as modeled with the
software and capsular threshold as determined clinically in five patients (31.2%).
Conclusions: In this pilot study, the VTA model software was of limited assistance
in identifying capsular thresholds for the whole cohort due to a large inter-patient
variability. Clinical testing remains the gold standard in selecting stimulation parameters
for STN-DBS in PD.
Keywords: Parkinson’s disease, deep brain stimulation, subthalamic nucleus, capsular prediction, volume of tissue
activated
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INTRODUCTION
Deep brain stimulation (DBS) of the subthalamic nucleus (STN)
is a well-established treatment for advanced Parkinson’s disease
(PD) (1). Numerous prospective and open-label studies have
demonstrated benefits of DBS for motor and non-motor signs,
as well as improved quality of life in PD (2–6). Initial DBS
programming is based on establishing and ranking contacts that
exhibit the larger therapeutic window, calculated as the difference
between stimulation amplitudes at persistent side effects and
meaningful improvement of rigidity (7). Side effects are either
related to stimulation of the sensorimotor part of the STN on its
own, or to current diffusion to neighboring structures including
limbic or cognitive parts of the STN, internal capsule (IC),
pallidothalamic tract, as well as the cerebellothalamic tract (8–
10). Thus, outcome greatly depends on the electrode position
and precise knowledge of the surrounding anatomy (11, 12). The
most prominent side effect is linked to current diffusion to the
corticospinal and corticonuclear tracts (CSNT) within the IC [see
Figure 1, adapted from Hamani et al. (13)]. Current diffusion
to the CSNT induces tonic muscle contractions, mainly in the
face area and fine muscles of the hand, and less frequently in
the lower limbs (14), likely reflecting somatotopic arrangement
of CSNT fibers in the vicinity of the STN. Dysarthria is related
to current diffusion to corticonuclear fibers that innervate
muscles involved in speech, i.e., lips, tongue, pharynx, and larynx
muscles (8, 14, 15). Although basic algorithms for programming
and troubleshooting sessions have been continuously refined,
computational modeling of DBS electric fields may potentially
provide new information that could be of further aid in DBS
programming sessions (16). These models allow calculation of
the volume of tissue activated (VTA), for instance, using a
diffusion tensor-based finite element neurostimulation model
(17). Recently, new directional electrodes have been developed
according to multiple independent current source control
technology (18, 19). As opposed to conventional electrodes,
directional electrodes are characterized by the ability to steer
current toward three distinct directions, not only along the Z-
axis (Z), but also in the horizontal plane (X, Y) (18, 19). While
conventional electrodes generate a spherical electrical field that
encompasses all adjacent structures equally, directional contacts
produce a limited and adaptable electrical field biased toward the
active contact (18, 19). Few studies have outlined the potential
interest of directional electrodes for patient management (7,
20, 21). Importantly, the number of individual stimulation
parameter combinations increases substantially with the use of
directional electrodes, making post-operative management more
challenging and time-consuming. Thus, clinical tools including
VTA models could be helpful in identifying effective parameter
settings for each patient more easily. The goal of this pilot study
was to evaluate the usefulness of a new software designed for
clinical practice in the refinement of DBS parameters.
Abbreviations: STN, subthalamic nucleus; DBS, deep brain stimulation; VTA,
volume of tissue activated; CTA, capsular threshold amplitude; VTA-CTA, VTA
modeled capsular threshold amplitude; IC, internal capsule; CSNT, corticospinal
and corticonuclear tracts.
FIGURE 1 | Anatomical relations between electrode position within the STN,
volume of tissue activated (VTA) illustrated by the red bubble, and surrounding
structures. STN, subthalamic nucleus; VTA, volume of tissue activated; GPi,
globus pallidus internus; GPe, globus pallidus externus; Put, putamen; SN,
substantia nigra; Thal, thalamus; IC, internal capsule; SF, subthalamic
fasciculus; AL, ansa lenticularis; LF, lenticularis fasciculus; ZI, zona incerta; ML,
medial lemniscus; FF, fields of Forel; H1, H1 field of Forel; H2, H2 field of Forel.
Adapted from Hamani et al. (13).
MATERIALS AND METHODS
Population
We enrolled 16 STN-DBS PD patients. All patients were
implanted with Cartesia directional devices (Boston Scientific,
Valencia, CA) (20, 22) that each contained one ventral and one
dorsal non-segmented ring (rings 1, 8 and 9, 16 for left and right
STN, respectively), and two segmented rings in between (one
ventral and one dorsal segmented ring), each containing three
contacts (contacts 2, 3, 4 and 5, 6, 7 for left STN ventral and dorsal
segmented rings, and contacts 10, 11, 12 and 13, 14, 15 for right
STN ventral and dorsal segmented rings, respectively).
Clinical Evaluation
We assessed monopolar reviews according to standard clinical
practice during one session after a 12-h overnight withdrawal
from dopaminergic medication as described previously (23). We
tested each electrode separately and kept the contralateral STN-
DBS ON for the patient’s comfort. We predefined a frequency of
130Hz and pulse width of 60 µs for all sessions. We determined
the capsular threshold amplitude (CTA) by testing for each
side the two non-segmented rings, the two segmented rings in
between on omnidirectional stimulation (vertical steering), as
well as the six directional contacts from the two segmented rings
(horizontal steering), which added up to a total of 10 measures
per electrode. We gradually increased current amplitude by
steps of 0.5mA until the appearance of a visible facial or limb
contraction. Then, we decreased the current amplitude in steps
of 0.1mA until the exact contraction threshold was reached (23).
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Capsular Threshold Modeling
We used the GuideTM XT software for all steps detailed in
this section. MB performed manual refinement of the IC
volume and AK performed capsular threshold determination on
the images using the VTA. We carried out all the modeling
procedures blinded from patients’ clinical evaluations, with
anonymization of the patient’s name on the MRI images. We
first performed coregistration of the preoperative 3D T1, specific
STN visualization T2 MRI sequences (3D T2 SPACE in sagittal
orientation, FOV 450mm, TR/TE 2400/225ms, flip angle 120◦),
and the post-operative CT scan. Then, an automatic anatomical
segmentation of the STN and the IC was computed. For each
patient, we manually refined the IC using both the T2 image and
the Schaltenbrand atlas (24), in order to extend IC boundaries
to the cerebral peduncles in the midbrain, a process that enables
visualization of the CSNT in the vicinity of the STN. Manual
refinement of the IC was the longest step of the process, and
took 10–15min per patient. Lead trajectories were automatically
reconstructed from the CT scans. We subsequently adjusted the
lead orientations determined from the post-operative sagittal and
coronal topograms using the radiopaque marker embedded in
each lead. Finally, we sequentially built VTAs by increasing the
current amplitude virtually for each contact tested until the VTA
border touched the capsule border.We labeled the corresponding
amplitude as the CTA of the VTA model (VTA-CTA).
Statistics
For each patient, we computed statistical analysis on the data
to test the correlation between the clinical thresholds and the
modeled capsular threshold. We used the corrcoef function of
the Matlab (Mathworks, Natick, MA) statistical toolbox. We
also performed a correlation analysis on the whole group and
normalized the data to compare patients by using the z-scores.
We then reported the resulting p and correlation coefficients r
for each patient. Lastly, we refined the analysis for the patients
who did not show any significant effect by separating the analysis
for the left and right hemispheres to see if the effect had been
hidden by one side where the modeling predicted the capsular
threshold poorly.
RESULTS
Population
We tested 29/32 STNs from 16 consecutive patients (6 women
and 10 men). Three STNs were ruled out given that no capsular
side effects were observed between 0 and 6mA, and CTA was not
determined. Mean patient age was 60.1± 2.0 years, andmean PD
duration was 10.5 ± 1.2 years. Mean presurgical MDS-UPDRS
part III scores in off and on drug conditions were 47.1 ± 4.0 and
14.3 ± 2.0, respectively, corresponding to a mean improvement
of 70.2 ± 3.5%. Monopolar reviews took place between 2.5 and
6 months after surgery (mean, 3.7 ± 0.2), and mean levodopa
equivalent daily dose (LEDD) before and after DBS were 1182.8
± 115.8mg and 452.6 ± 88.4mg, respectively, corresponding
to a mean reduction of dopaminergic therapy dosage of 60.9 ±
7.5% (25).
Clinical Threshold vs. Capsular Threshold
At the group level, when performing statistical analysis on the
z-scored capsular thresholds, we found a significant correlation
(p = 0.0001), with a relatively low regression coefficient (r
= 0.2445). When considering intra-patient analysis, we found
significant (p < 0.05) correlations between capsular threshold as
modeled with the software and capsular threshold as determined
clinically in five patients (see Figure 2). In these five patients,
the resulting mean correlation coefficient was 0.70 (±0.16).
Furthermore, in one additional patient, there was a tendency
toward significant correlation (p= 0.0746).
Vertical and Horizontal Virtual Current
Steering
We analyzed virtual current steering in patients for whom CTA
was correctly predicted by the VTA-CTA model. We arbitrarily
chose the constant parameter settings as follows: 3mA, 60 µs,
and 130Hz. Then, we built a VTA according to the software
and successively considered the vertical and horizontal virtual
current steering (see Figure 3). Vertical virtual current steering
consisted of representing the lead position and overlap between
the VTA and STN automatically segmented by the software.
Horizontal virtual current steering consisted of representing the
lead position and overlap between VTA, STN, and IC in the
best ring previously identified, in order to rank its contacts from
lowest to highest capsular threshold.
DISCUSSION
In this pilot study, we tested the hypothesis that VTA
model software could help clinicians with capsular threshold
determination in STN-DBS PD patients during post-operative
management. To do this, we retrospectively compared predicted
capsular thresholds modeled using the software with clinical
capsular thresholds clinically assessed during the monopolar
review in 16 STN-DBS PD patients.
At the group level, we found a significant correlation (p =
0.0001), between image-defined and clinically defined capsular
thresholds, but the regression coefficient was relatively low (r =
0.2445 points). Intra-patient analyses showed significant (p <
0.05) correlations in only 5/16 patients (31.2%), meaning that
for each of these patients, contacts were accurately ranked by
the software from the lowest to the highest capsular threshold.
The low regression coefficient in analysis at the group level
can therefore be explained by some variability of the tool as
confirmed in intra-patient analyses, with an excellent matching
in some, but not all, of the patients.
Although the small size of this pilot study, a lack of statistical
power, and a learning curve effect for both clinical and VTA-
modeled capsular threshold measurements must be mentioned
first, factors related to the different steps needed for capsular
threshold modeling may be considered one by one to explain the
discrepancy observed between global and intra-patient analyses.
Coregistration between preoperative 3D T1, specific STN
visualization T2 MRI sequences, and the post-operative CT scan
was performed automatically by the software. Visual inspection
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FIGURE 2 | Table of correlation coefficients and associated p-values between GuideTM XT predicted capsular threshold and clinically measured threshold. Examples
of scatterplots from one good correlation (P4) and one bad correlation result (P13). The number of calculated capsular thresholds per patients is indicated in the first
column.
of coregistration quality was systematically performed before
anatomical segmentation. Coregistration was correctly done in
all cases and does not appear to be a critical factor contributing
to the variability observed between patients.
Anatomical segmentation in the software does not include
the CSNT per se but the IC, which does not integrate
the diencephalic–mesencephalic junction. Thus, in order to
determine the VTA-modeled capsular threshold, we manually
drew the CSNT in the vicinity of the STN, by extending
the automatically segmented IC from the diencephalon to
the mesencephalon. Nevertheless, this step, the longest of the
capsular threshold modeling, was not highly reproducible, which
might broadly explain the variability observed from one patient
to another. One would expect that capsular threshold as modeled
with the software depends on the distance between the internal
border of the CSNT drawnmanually and the lead where the VTA
is built. In the near future, tractography could be a great help to
reduce this bias (24–27).
Determination of the electrode position from the post-
operative CT scan and coregistration of the CT with the T1 pre-
operative MRI is also associated with some intrinsic limitations
of the software, namely, electrode position reconstruction from
the CT artifact, brainshift pre- and post-implantation, and T1
image artifacts.
Lead orientations that have been performed manually from
the topograms (sagittal and coronal views) may also constitute
a source of error in the modeling as they can change the
determination of the capsular threshold between the three
contacts at each depth of directional contact. Methods such as 3D
rotational fluoroscopy and CT scan-based algorithms have been
developed to determine orientation automatically with higher
precision and less variability, but had not been included in the
software at the time of the study (28, 29).
The VTA model used by the software for capsular threshold
modeling is a critical point to discuss. The model makes several
assumptions that influence its threshold estimates. The first is
a simplified electrical medium that represents the brain as a
homogenous and isotropic volume conductor. This means that
every point in the model has the same electrical conductivity
value (homogeneous) and that those conductivity values are
the same in every direction (isotropic). Heterogenous and
anisotropic estimates of tissue conductivity are an area of
ongoing research (30). Furthermore, we do not know the
amplitude range for which the model is valid (power dispersion
in biological anisotropic tissue). Additionally, all axons in the
model are assumed to be equal in diameter, perfectly straight,
and running perpendicular to the trajectory of the lead. The
diameter of an axon is known to strongly influence its excitability
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FIGURE 3 | Example of vertical (A) and horizontal (B) virtual current steering with GuideTM XT. Vertical virtual current steering (A) shows that contact 1 is within the
ventral part of the STN, and contact 8 is outside the STN. Ventral (2–4) and dorsal (5–7) rings are within the ventromedial and dorsolateral parts of the STN,
respectively. According to horizontal virtual current steering (B), modeled VTA of contact 7, “the best contact,” does not touch the CSNT, whereas modeled VTA of
either the ring or contact 6, “the worst contact,” shows current diffusion touching the CSNT. VTA (in blue): volume of tissue activated modeled by GuideTM XT, STN (in
green): subthalamic nucleus automatically segmented by GuideTM XT, internal capsule (in red) including CSNT manually refined: corticospinal and corticonuclear tracts.
(31), and the IC exhibits axons with a range of diameters (32).
Furthermore, the trajectory and orientation of the axons also
influence the excitability of the model. These model assumptions
were instituted both to simplify the model and to tend toward the
side of excitability.
Despite the multiple sources of error and current limitations
discussed above, the software could offer the opportunity to
obtain a more comprehensive anatomy-based approach for
directional DBS and potentially less time-consuming bedside
management for a given patient. Although clinical capsular
threshold determination remains the gold standard, VTA model
software could be a useful tool for the refinement of parameter
settings in patients for whom the clinical threshold and VTA
modeled threshold are congruent (see Figure 3). Vertical virtual
current steering, which consists of arbitrarily choosing constant
parameter settings, for instance: 3mA, 60 µs, 130Hz, and
drawing the VTA for the four electrode levels may help
clinicians to visualize the lead position within the STN and
the overlap between the VTA and the sensorimotor part of
the STN. This virtual approach may help to more rapidly
determine the best anatomical match out of four levels for
stimulation from ventral to dorsal, targeting the sensorimotor
STN for optimal improvement in parkinsonism. Horizontal
virtual current steering, which consists of arbitrarily choosing
constant parameter settings, for instance: 3mA, 60 µs, 130Hz,
and drawing the VTA for the three contacts contained in
one segmented ring, could illustrate overlap between the VTA,
STN, and IC in order to rank contacts from the lowest to the
highest capsular threshold. Such information could be valuable in
determining visually guided and anatomically based horizontal
steering strategies, when stimulation is limited by side effects
related to current diffusion to surrounding fiber systems such
as the CSNT. This approach could also be extended to other
DBS side effects such as paresthesia, which is related to current
diffusion to the medial lemniscus.
CONCLUSION
In this pilot study, software that superimposes VTA and anatomy
was of limited assistance in the identification of capsular
thresholds for the whole cohort due to large inter-patient
variability. So far, this new tool allows visualization of the IC,
but it has not been designed to identify corticonuclear and
corticobulbar tracts inside this very large structure. Integration
of fiber tracking tools that can visualize these fiber systems
might lead to a better match between visual modeling and
clinical testing, which would be an important first step to a more
automatized post-operative management of DBS. Currently,
clinical testing remains the gold standard in selecting stimulation
parameters for STN-DBS in PD. Further studies with larger
sample sizes remain mandatory to assess the usefulness of
VTA model software for practical management of STN-DBS
PD patients.
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